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Expression of thyroid hormone transporters in the human placenta and changes 
associated with intrauterine growth restriction. 
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Abstract 
Thyroid hormones (TH) are important for the development of the human fetus and 
placenta from very early gestation. The transplacental passage of TH from mother to fetus 
and the supply of TH into trophoblasts require the expression of placental TH plasma 30 
membrane transporters. We describe the ontogeny of the TH transporters MCT8, MCT10, 
LAT1, LAT2, OATP1A2 and OATP4A1 in a large series (n=110) of normal human 
placentae across gestation and describe their expression changes with intrauterine fetal 
growth restriction (IUGR n=22). Quantitative RT-PCR revealed that all the mRNAs 
encoding TH transporters are expressed in human placenta from 6 weeks gestation and 35 
throughout pregnancy. MCT8, MCT10, OATP1A2 and LAT1 mRNA expression increased 
with gestation. OATP4A1 and CD98 (LATs obligatory associated protein) mRNA 
expression reached a nadir in mid-gestation before increasing towards term. LAT2 mRNA 
expression did not alter throughout gestation. Immunohistochemistry localised MCT10 and 
OATP1A2 to villous cytotrophoblasts and syncytiotrophoblasts, and extravillous 40 
trophoblasts while OATP4A1 was preferentially expressed in the villous 
syncytiotrophoblasts. Whilst MCT8 protein expression was increased, MCT10 mRNA 
expression was decreased in placentae from IUGR pregnancies delivered in the early 3rd 
trimester compared to age matched appropriately grown for gestational age controls. No 
significant change was found in the mRNA expression of the other transporters with IUGR. 45 
In conclusion, several TH transporters are present in the human placenta from early 1st 
trimester with varying patterns of expression throughout gestation. Their coordinated 
effects may regulate both transplacental TH passage and TH supply to trophoblasts, which 
are critical for the normal development of the fetus and placenta. Increased MCT8 and 
decreased MCT10 expression within placentae of pregnancies complicated by IUGR may 50 
contribute to aberrant development of the fetoplacental unit. 
3 
Introduction 
Thyroid hormones (TH) are essential for normal human fetal growth and development, 
particularly the central nervous system (CNS). Even minor perturbations in maternal 55 
thyroid status are associated with neurodevelopmental abnormalities in children in later life 
[1, 2]. These effects are most pertinent when maternal thyroid dysfunction occurs before 
the onset of endogenous fetal TH production in the mid-trimester of pregnancy [3]. Current 
evidence points to a direct role for maternal TH in human fetal CNS development from the 
1st trimester of pregnancy [4, 5] and this necessitates the transplacental passage of 60 
maternal TH to the fetus. Transplacental transport of maternal TH is evidenced by the 
finding of a biologically significant concentration of free thyroxine (T4) in fetal coelomic 
fluid and in fetal tissues from as early as five weeks of gestation [6, 7]. Even at term, the 
concentration of maternally-derived T4 in the circulation of fetuses with absent 
endogenous thyroid function reaches 25-50% of normal [8]. 65 
The human placenta is also a TH responsive organ, with both villous and extravillous 
trophoblasts (EVTs) expressing specific TH nuclear receptor isoforms for triiodothyronine 
(T3, the active ligand) [9]. TH can affect human trophoblast proliferation, migration and 
invasion in vitro [10-12]. These characteristics, expressed principally by human EVTs, play 
a key role in maternal spiral artery remodelling. Deficiencies in this process lead to 70 
malplacentation syndromes. Clinical conditions associated with malplacentation (including 
miscarriages, pre-eclampsia, abruption, intrauterine growth restriction (IUGR) and 
stillbirths) are associated with untreated maternal thyroid disorders [13]. Even subclinical 
hypothyroidism is associated with miscarriages and preterm delivery [14, 15], suggesting 
that utero-placental tissues are sensitive to minor perturbations in maternal thyroid 75 
function. 
The human haemochorial placenta forms a barrier across which any maternal-fetal 
exchange must take place. The cellular uptake of T4 and T3 by the placenta is thus critical 
4 
for both TH action within this organ and for TH transport to the fetus. There is clear 
evidence that the cellular influx and efflux of TH occur mostly through plasma membrane 80 
transporters [16]. The importance of TH transporters during development has been 
supported by the discovery of mutations in the gene encoding the TH transporter, MCT8, 
resulting in subjects displaying severe global neurological impairment accompanied by 
elevated serum free T3 but low free T4 concentrations [17-19]. Although to date it has 
been assumed that the phenotype is due primarily to defective TH transport into neurons 85 
within the CNS [20], the possibility of impaired TH transport across the placenta also has 
to be considered. 
The ability to transport TH has been described in members of different transporter groups 
including the monocarboxylate transporters (MCT), L-type amino acid transporters (LAT) 
and organic anion transporting polypeptides (OATP). With the exception of MCT8, these 90 
transporters do not exclusively transport TH and they all have slightly different affinities for 
specific forms of TH (Table 1). To date six different TH transporters are known to be 
present in the placenta: MCT8, MCT10, LAT1, LAT2, OATP1A2 and OATP4A1 but their 
relative contributions to placental TH transport are unknown [21-26]. We have previously 
reported an increase of MCT8 mRNA expression with advancing gestation [21] but there is 95 
limited information regarding the ontogeny of the other TH transporters.  
IUGR is often secondary to malplacentation with evidence of altered placental histology 
and cytoarchitecture [27]. Babies born with IUGR are major contributors to perinatal and 
neonatal mortality. Furthermore, IUGR survivors have neurodevelopmental scores that are 
significantly lower at age 3 and poorer school performances as teenagers compared to 100 
controls [28, 29]. Altered thyroid status is one of several factors postulated to play a role in 
this morbidity, especially in development and function of the CNS and placenta [5, 30]. We 
and others have reported a significant reduction in circulating concentrations of free T4 
and T3 by in utero cordocentesis of fetuses affected by severe IUGR [9, 31]. We also 
5 
reported that in the very severe cases of IUGR, which required delivery in the early 3rd 105 
trimester of pregnancy, placental MCT8 expression was significantly higher compared to 
gestationally-matched controls [21]. 
In this study, we determined the expression of the TH transporters MCT10, OATP1A2, 
OATP4A1, LAT1, LAT2 and the LATs obligatory associated protein, CD98, alongside 
MCT8 in a large series of normal human placentae across gestation. In order to determine 110 
whether aberrant expression of TH transporters within placentae from IUGR pregnancies 
may contribute to malplacentation and the development of hypothyroxinaemia in the fetus, 
we assessed the expression of TH transporters in placentae from pregnancies 
complicated by IUGR. 
115 
6 
Material and Methods: 
Collection of placental samples 
This study was approved by the Local Research Ethics Committee (South Birmingham) 
and the Research and Development Committee of  the Birmingham Women’s Hospital. A 
total of 110 normal placental samples were collected and grouped as follows: 6-10 weeks 120 
of gestation (wks; n=39), 11-14 wks (n=18), 15-20 wks (n=4), 27-34 wks (n=9) and term 
(37-41 wks; n=40). The gestational ages of the pregnancies were determined by 1st 
trimester ultrasound scan [21]. Placentae from 6 to 20 wks were obtained from surgical 
termination of pregnancy for reasons other than fetal abnormality (in accordance with the 
Polkinghome Report and the Human Tissue Act, UK). The normal early 3rd trimester group 125 
(27-34 wks) consisted of placentae with appropriately grown fetuses for gestational age 
(AGA) which were obtained following emergency caesarean section for placenta praevia 
(n=3), maternal tumours (n=3) and prelabour rupture of membranes (with no clinical 
evidence of infection) with a breech presentation (n=3). The normal late 3rd trimester group 
(37-41 wks) consisted of placentae from normal pregnancy delivered by elective 130 
caesarean section for previous caesarean section, breech presentation or patient choice. 
Twenty-two cases of IUGR in the absence of maternal hypertension were diagnosed 
prospectively using ultrasound as described previously [32]. Cases satisfied at least three 
of the following four criteria: i) fetal abdominal circumference < the 3rd centile for gestation, 
ii) reduced abdominal circumference growth velocity over 14 days, iii) oligohydramnios and 135 
iv) abnormal umbilical artery Doppler velocity waveforms. None of the babies had known 
chromosomal or structural abnormalities. These criteria selected a severe and relatively 
homogenous phenotype. Seventeen IUGR placentae were collected at 25-32 wks (early 
onset) and five at 37-38 wks (late onset). The early onset IUGR group represents a more 
severe phenotype within the IUGR disease spectrum with a 53% neonatal mortality rate. 140 
7 
All placentae were collected from pregnancies delivered by caesarean section without 
labouring. Immediately after delivery, multiple random biopsies were obtained by 
dissecting the placental tissue off the chorionic plate then washed, snapped frozen and 
stored at –80oC as previously described [32].  
Compared to our previous report describing the placental expression of MCT8 [21], our 145 
present series of normal and IUGR placentae is increased by 55% (71 to 110) and 120% 
(10 to 22) respectively, and includes the previously analysed samples. In view of this 
significant rise in sample size, we repeated our study of MCT8 alongside the other TH 
transporters.  
In addition, for immunohistochemistry, matched placental and placental bed biopsies were 150 
obtained following elective pregnancy termination at 8-12 wks and after elective caesarean 
section at term [33]. All placental bed biopsies were selected to include interstitial EVTs, 
‘transformed’  decidual  and/or  myometrial  spiral  arteries  containing  endovascular  and/or 
intramural EVTs.  
RNA extraction 155 
Approximately 100mg of placental tissue were homogenised and total RNA was extracted 
with TRI reagent (Sigma-Aldrich)  following  the  manufacturer’s  guidelines.  RNA  (0.5μg) 
was reverse transcribed using Avian Myeloblastosis Virus (AMV) reverse transcriptase 
(Promega) in a reaction volume of 20 µl following manufacturer’s guidelines [32]. Following 
reverse transcription (RT) the reaction mixture was diluted 1:2 with RNAse free water. 160 
Quantitative TaqMan PCR 
Expression of mRNAs encoding MCT8, MCT10, OATP1A2, OATP4A1, LAT1, LAT2 and 
CD98 was determined using the ABI PRISM 7500 Sequence Detection System as 
described previously [32]. TaqMan PCR was carried out  in duplicate using 1μl of  the RT 
reaction in a reaction volume of 25 µl in 96 well plates; the reaction buffer contained 1x 165 
TaqMan Universal PCR Master Mix (Applied Biosystems, UK), 150 nM TaqMan probe (5’ 
8 
FAM  /  3’  TAMRA  labelled; Eurogentec, UK) and 900 nM primers (AltaBioscience, UK). 
Each probe and primer set was designed with Primer Express v2.0 (ABI) with all 
amplicons crossing an exon-exon boundary (Table 2) and validated alongside control RT 
reactions without AMV. All samples were analysed for 18S rRNA with a VIC-labelled-probe 170 
and primers (ABI) as an internal control either in singleplex (OATP1A2, OATP4A1 and 
LAT2) or multiplex (MCT8, MCT10, LAT1 and CD98). Amongst several housekeeping 
genes we investigated, 18S ribosomal RNA gave the best stability value and the least 
intra- and inter- group variability in agreement with a previously published report [23]. 
Data were expressed as Ct values and relative quantifications of each gene were 175 
determined  using  the  ∆Ct  method.  For  each  sample,  fold  changes  in  gene  expression 
were calculated with the equation 2-∆Ct (∆Ct  =  sample  Ct  minus  calibrator  Ct).  The 
calibrator was determined for each gene as the sample with the highest expression. For 
each sample, transporter gene expression was then normalised to 18S to correct for 
differences in RT efficiency. The mean gene expression for the normal term placenta 180 
samples was assigned the arbitrary value of 1. The relative mRNA expression for each 
sample compared to the mean for term placenta was calculated and used to perform 
statistical analysis. 
Western blot 
Placental proteins were extracted from randomly selected samples from each gestational 185 
group (6-10 wks n=2; 11-14 wks n=4; 15-20 wks n=2; 27-34 wks n=4; term n=4). Placental 
tissues were homogenised in lysis buffer with protease inhibitors as previously described 
[21]. Protein samples (30 µg) were denatured (1 hr, room temperature) in loading buffer 
(Laemmli sample buffer with dithiothreitol at 54mg/ml), separated by electrophoresis in 
10% SDS-PAGE gels and blotted on nitrocellulose membranes. Blots were then probed 190 
with primary antibody: rabbit polyclonal antisera to MCT8 (Ab4790), MCT10 (described in 
[34]), OATP1A2 or OATP4A1 (described in [35]) or anti-human CD98 goat polyclonal 
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antibody (Santa Cruz). Primary antibodies were used at 1:500, with the exception of the 
anti-CD98 (1:250). Blots were then probed with secondary antibody conjugated to 
horseradish peroxidase and bands visualised using the ECL chemiluminescence detection 195 
kit (GE Healthcare Life Sciences). ß-actin expression was used to assess protein loading. 
Relative densitometry for each protein normalised to β-actin was performed using 
GeneTools Analysis software (Syngene, Synoptics Ltd). To demonstrate the specificity of 
the MCT8 antibody, Ab4790 was tested on MCT8-null JEG-3 choriocarcinoma cells 
transfected with pcDNA3.1-hMCT8 that encodes the human MCT8 protein [36]. This 200 
revealed a band at ~ 60 kDa on Western blot (Fig. 1E), consistent with the expected size 
of the MCT8 protein, which disappeared following pre-incubation with the blocking peptide 
(data not shown). 
Immunohistochemistry 
Formalin-fixed paraffin-embedded sections (3µm) of placental and placental bed biopsies 205 
were immunostained for MCT10, OATP1A2 and OATP4A1 using an avidin-biotin 
peroxidase technique (Vectastain Elite, Vector Laboratories) as previously described [10, 
21]. All reagents were prepared as per the kit instructions. Rabbit polyclonal primary 
antibodies to MCT10, OATP1A2 or OATP4A1 were used at 1:250, 1:150 and 1:300 
respectively. Negative controls were performed for each sample by replacing the primary 210 
antibody with non-immune serum. Sections were lightly counterstained with Mayers 
haematoxylin, dehydrated, cleared and mounted in synthetic resin. 
Statistical Analyses 
Since the gene expression data did not follow a normal distribution, non-parametric tests 
were employed using the Prism software (GraphPad Software Inc). Comparisons between 215 
gestational age groups were performed by one-way Kruskal-Wallis ANOVA test with post-
hoc  Dunn’s  multiple  comparison  tests.  Comparisons  between  IUGR  and  AGA  samples 
were performed by two-way ANOVA with Bonferroni post-hoc tests. Significance was 
10 
taken as p<0.05. All the significant differences from post-hoc tests are indicated in the 
figures.220 
11 
Results  
Increased expression of mRNAs encoding MCT8 and MCT10 was demonstrated with 
advancing gestation (ANOVA p<0.0001; Fig. 1A-B). Of all the TH transporters studied they 
also showed the greatest difference in expression between early gestation and term 
samples. Compared to term, MCT8 and MCT10 mRNAs were expressed 4-fold and 12-225 
fold less respectively at 6-10wks (p<0.001 for both). By 27-34 wks, MCT8 and MCT10 
mRNA expression had risen to levels similar to term. Western blot confirmed that both 
MCT8 and MCT10 proteins were expressed from the 1st trimester and throughout 
pregnancy (Fig. 1C-D). MCT8 protein expression increased with gestational age (p<0.05), 
with expression in the 1st trimester being 29% less than at term (p<0.05, Fig. 1F). There 230 
was also a trend of increased MCT10 protein expression with gestational age (p=0.0685, 
Fig. 1G). Immunohistochemical analysis of 1st trimester placental biopsies indicated that 
MCT10 protein was present in both villous syncytiotrophoblasts and cytotrophoblasts, with 
more marked immunostaining in the cytotrophoblast layer (Fig. 1H1). In normal term 
placenta immunoreactivity remained in villous syncytiotrophoblasts (Fig. 1H2). Throughout 235 
gestation there was also relatively weak immunoreactivity within stromal cells of the villous 
placenta. In the 1st trimester placental bed, MCT10 staining was also found in EVTs and 
decidual stroma (Fig. 1H3). 
Placental expression of OATP1A2 mRNA was significantly lower before 14 wks compared 
to term (ANOVA p<0.01, Fig. 2A); being expressed 1.8-fold less at 6-10 wks compared to 240 
term (p<0.05) but rising to term levels by 27-34 wks. In contrast, OATP4A1 mRNA 
demonstrated different changes with gestation (ANOVA p<0.01; Fig. 2B): OATP4A1 
expression at 6-10 wks was similar to term levels but was reduced by 5-fold at 11-14 wks 
compared to term (p<0.05) thus reaching a nadir in mid-gestation before increasing 
towards term levels by 27-34 wks.  245 
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The presence of OATP1A2 and OATP4A1 proteins throughout gestation in placenta from 
normal pregnancies was confirmed by Western blot (Fig. 2C-D). As described previously 
in brain and liver, several glycosylated forms of OATP1A2 were expressed [37, 38] and 
they were more abundant in samples before 20 wks than in 3rd trimester samples. 
Densitometry analysis of the bands between 60 and 85kDa showed no statistical 250 
difference in OATP1A2 protein expression with gestational age. Equally, there was no 
statistically significant change in OATP4A1 protein expression with gestational age.  
Immunohistochemistry demonstrated focal but strong immunoreactivity in villous 
syncytiotrophoblasts for both OATP1A2 and OATP4A1 in the 1st trimester, with 
immunostaining becoming more diffuse but weaker at term (Fig. 2E-F). Where present, 255 
OATP4A1 appeared preferentially localised to the apical surface of syncytiotrophoblasts. 
OATP1A2 demonstrated moderately strong immunostaining on villous cytotrophoblasts 
and EVTs throughout gestation but immunostaining for OATP4A1 in these cells was weak 
(Fig. 2E). 
Both light (LAT1, LAT2) and heavy (CD98) chains of the system L amino acid transporters 260 
were expressed from 6 wks and throughout gestation (Fig. 3). Whereas quantification of 
LAT2 mRNA showed no change across gestation, quantification of LAT1 and CD98 mRNA 
indicated significant changes with advancing gestation (ANOVA p<0.0001 and p<0.05 
respectively). LAT1 mRNA expression was lower before 20 wks; being expressed 2.6-fold 
less at 6-10 wks compared to term (p<0.001) but increasing to term levels by 27-34 wks. 265 
CD98 mRNA expression was significantly reduced at 11-14 wks compared to term 
(p<0.05), thus reaching a nadir in the late 1st trimester and very early 2nd trimester. CD98 
Western blot confirmed the presence of protein from the early 1st trimester and throughout 
gestation, with no statistically significant differences with gestational age (Fig. 3E).  
To investigate whether changes in TH transporter expression are associated with 270 
malplacentation, we assessed the expression of the TH transporters in 3rd trimester 
13 
placentae from both early (25-32 wks) and late onset (37-38 wks) IUGR pregnancies 
compared to gestationally-matched AGA pregnancies. 
Quantification of mRNA encoding MCT8 in our current expanded series of placental 
samples showed no statistical differences between placentae from pregnancies 275 
complicated by IUGR and placentae from gestationally-matched AGA controls for both the 
early and late onset groups (Fig. 4A). However, densitometry analysis of Western blots 
showed a 27% increase in MCT8 protein expression in early onset IUGR compared to 
gestationally-matched AGA controls (p<0.05) (Fig. 4B and 4C). The late onset IUGR 
samples showed no difference in MCT8 protein expression compared to term AGA 280 
controls.  
In early onset IUGR the relative expression of MCT10 mRNA was 5-fold lower compared 
to gestationally-matched AGA controls (p<0.05) (Fig. 4D). At the protein level, in keeping 
with mRNA data, the early onset IUGR samples showed a trend toward decreased MCT10 
expression compared to gestationally-matched AGA controls (10% decrease, p=0.094; 285 
Fig. 4E and 4F). No statistically significant differences were seen with the late onset IUGR 
samples compared to AGA samples at both the mRNA and protein levels. 
Messenger RNA encoding OATP1A2, OATP4A1, LAT1, LAT2 and CD98 were found at 
similar levels in placentae from IUGR pregnancies compared to gestationally-matched 
AGA controls (Fig. 5) 290 
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Discussion 
In this study we have described the expression of six major TH transporters 
simultaneously in a large series of human placentae from as early as 6 wks and 
throughout gestation. This study is also the first to report on changes in the placental 295 
expression of TH transporters associated with IUGR.  
Expression of mRNAs encoding MCT8, MCT10, OATP1A2 and LAT1 were significantly 
lower prior to 14 wks compared to term while OATP4A1 and CD98 mRNA expression at 6-
10 wks was similar to term but fell to a nadir in the late 1st and early 2nd trimesters. Our 
findings are largely in agreement with previous studies on much smaller sample sizes 300 
collected across a limited range of gestational ages. Patel et al [23] showed a decreased 
mRNA expression of OATP1A2 but no change for OATP4A1 at 9-12 wks compared to 
term. In accord with our findings, CD98 mRNA has been reported throughout gestation 
[39] and lower placental expressions of CD98 and LAT1 protein at 12-21 wks compared to 
term have been reported [40]. Although the presence of mRNAs encoding MCT10 and 305 
LAT2 has been described in human term placenta [22, 24], this is the first report of their 
ontogeny across gestation. 
We describe for the first time the localisation of MCT10 and OATP1A2 protein in both 
villous syncytiotrophoblasts and cytotrophoblasts, as well as in EVTs. Such widespread 
localisation is similar to what we have previously reported for MCT8 [21]. In contrast, 310 
OATP4A1 protein was preferentially localised in villous syncytiotrophoblasts throughout 
gestation, confirming a previous report on term placenta [26]. Other studies have also 
reported LAT1 and CD98 expression in the syncytiotrophoblast layer at term [40, 25] and 
LAT2 activity has been described in both the apical and basal membranes of the villous 
syncytiotrophoblast [41, 42]. 315 
The implications of the expression patterns of the TH transporters across gestation should 
be considered both in the context of placental development and of maternal to fetal 
15 
transfer of TH. The differentiation of primary cytotrophoblasts into EVTs, that invade 
maternal uterine tissues and transform maternal spiral arteries, is a tightly regulated 
process. Both T3 and T4 stimulate EGF production by primary cytotrophoblasts, in turn 320 
enhancing their survival [11]. In primary EVTs, T3 has been shown to suppress apoptosis 
[43] and promote invasion [12], whilst in an EVT-like cell line, T3 in conjunction with EGF, 
suppresses proliferation and increases cell motility [10]. The expression of MCT8, MCT10 
and OATP1A2 in both cytotrophoblasts and EVTs during the 1st trimester of pregnancy 
could allow TH cellular uptake into target cells and thus mediate TH action during early 325 
placental development. Moreover, the generally reduced levels of TH transporter 
expression at the time of invasion between 11 to 20 wks may reflect the need to regulate 
the pro-invasive effects of TH in order to prevent aggressive uncontrolled trophoblast 
invasion whilst promoting normal placentation. 
The primary placental cell barrier to free maternal-fetal exchange is the 330 
syncytiotrophoblast layer of placental villi, which is in direct contact with maternal blood. 
Cytotrophoblasts form an additional inner layer of cells across which TH have to pass 
during the first half of pregnancy [44]. The presence of MCT8 [21], MCT10 (present 
report), OATP4A1 [26] and LAT1 [25] in villous syncytiotrophoblasts and MCT8 [21], 
MCT10 and OATP1A2 (present report) in cytotrophoblasts from the early 1st trimester 335 
indicate that the required molecular apparatus for maternal to fetal transfer of TH are 
present from very early human gestation. Preferential localisation of MCT8, OATP4A1 and 
LAT1 at the apical membrane of syncytiotrophoblasts [21, 25, 26] suggests that these 
transporters play a key role in TH uptake directly from maternal blood. MCT10, which is 
preferentially localised in cytotrophoblasts in the 1st trimester, may have a key role in TH 340 
efflux from the trophoblast cell barrier to the fetus. 
The expression of multiple TH transporters at the trophoblastic cell barrier suggests that 
there is potential for redundancy in the TH uptake system from maternal blood. These TH 
16 
transporters with different affinities for specific forms of TH (Table 1), as well as for other 
compounds which can act as competitive inhibitors (with the exception of MCT8), probably 345 
offers flexibility to ensure that the requisite amount of TH is available for fetal development 
at each stage of gestation. Since the fetal circulating TH concentration and fetal brain TH 
content is closely correlated to maternal free T4 rather than free T3, free T4 is believed to 
be the major form of TH transported across the placenta [3]. During pregnancy maternal 
free T4 levels fluctuate between 13.5 to 17.5 pmol/l [45]. Fetal free T4 levels reach 350 
approximately 40-50% of maternal concentrations by the early 2nd trimester [6] and peak in 
the early 3rd trimester to 19.3 pmol/L and remain at levels above corresponding maternal 
concentrations [45]. Although, maternal and fetal free T4 concentrations are well below the 
Km values of all the TH transporters, the relatively lower Km for TH compared to the other 
compounds transported by the TH transporters (Table 1) should help TH to compete 355 
favourably. 
In addition, it is likely that the lower expression of MCT8, MCT10, OATP1A2 and LAT1 
before 14wks compared to term, as well as the nadir in OATP4A1 and CD98 expression in 
the late 1st and early 2nd trimester, may play a role in the necessary limitation of maternal-
fetal TH transfer, particularly around the time of onset of endogenous fetal TH production 360 
in the early 2nd trimester [3]. Increased expression of TH transporters in late gestation is 
consistent with the proposal that there is continued/increased maternal to fetal supply of 
TH in the 3rd trimester despite increasing fetal TH production [8, 46]. It is also likely that 
increased expression of these transporters with gestation may also fulfil the increased 
need for other biological substances for fetal growth and development, such as amino 365 
acids. The factors regulating the placental expression of these transporters are unknown. 
There are suggestions in rodents that the activity of system L and the expression of MCT8 
in non-placental tissues are influenced by thyroid status [47, 48] suggesting that TH may 
be a regulator of its own transporters. Further studies measuring functional activity of each 
17 
transporter are required to clarify their respective physiological significance in regulating 370 
transplacental TH supply. 
We hypothesised that alterations in TH transporter action within IUGR placentae may 
contribute to both malplacentation and fetal hypothyroxinaemia. In contrast to our previous 
study based on a significantly smaller series [21], our current report shows that MCT8 
mRNA expression was not increased in either early or late 3rd trimester IUGR placentae. 375 
However, at the protein level, increased MCT8 expression was still observed in 
representative samples of early 3rd trimester IUGR placentae compared to AGA controls. 
Very little is known about the regulation of MCT8 expression and protein stability. Post-
translational modulation is likely to be involved and such modifications have been reported 
in other plasma membrane transporters [49]. 380 
It has been reported that the transport of large neutral amino acids by system-L is reduced 
in syncytiotrophoblasts isolated from IUGR placentae [50]. Our mRNA findings have not 
reflected this observation. Contrary to a study by Jansson et al. on isolated 
syncytiotrophoblasts, our study assessed gene expression in placental homogenates that 
comprised many cell types. Post-transcriptional and post-translational regulation of 385 
system-L transporters could also be responsible for this difference [51]. 
In our present study, we reported for the first time that MCT10 mRNA expression is 
decreased in the early 3rd trimester of pregnancy in human villous placentae affected by 
severe IUGR compared to gestationally-matched AGA controls. Since MCT10 is widely 
expressed in villous and extravillous trophoblasts from an early gestational age it is 390 
possible that reduced MCT10 expression in early pregnancy could result in decreased 
local TH supply to trophoblasts thus compromising their proliferation and invasive 
capacity. However, the reduction in MCT10 expression in IUGR placentae at very early 
gestation is impossible to confirm since the clinical manifestation of fetal growth restriction 
as a consequence of malplacentation can only be diagnosed later in pregnancy. 395 
18 
Depending on the relative contributions made by each transporter to maternal-fetal 
transfer of TH, the combination of possible reduced transport by MCT10 and system-L 
may not be adequately compensated for by increased MCT8 expression and thus may be 
a contributory factor to fetal hypothyroxinaemia in IUGR pregnancies.  
In summary, our present study demonstrates that a range of TH transporters are present 400 
in the human placenta from the 1st trimester. Their coordinated effects may regulate both 
transplacental TH passage from mother to fetus and the development of the placenta itself 
through the progress of gestation. Changes in placental TH transporter expression 
associated with IUGR may be part of the pathophysiology of the condition.  
405 
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Figure Legends 
Fig. 1. MCT8 and MCT10 ontogeny in human placenta. A, B: Relative mRNA 415 
expression (mean +/- sem) in human placentae from 6 to 34 wks compared to term, given 
an arbitrary value of 1; **p<0.01, ***p<0.001 compared to term; +p<0.05 and ++p<0.01 
compared to 27-34 wks. C, D: Western blot on placental homogenates from normal human 
placentae (8 to 40 wks) demonstrating a band at ~60kDa for MCT8 (C) and ~50kDa for 
MCT10 [34] (D). Immunoblotting for -actin on the same blot was used to assess protein 420 
loading. E: Specificity of the MCT8 polyclonal antibody was tested in MCT8 null JEG3 cells 
transfected with empty vector (VO) or MCT8 plasmid (MCT8) and placental homogenates 
from normal human term placentae (Term PL). F, G: Densitometry of the protein bands 
shown in C and D respectively; *p<0.05. H: Representative sections demonstrating 
MCT10 immunoreactivity in 1st trimester (H1), term (H2) placenta and in 1st trimester 425 
placental bed (H3). Villous cytotrophoblasts are shown by arrows, syncytiotrophoblasts by 
arrowheads and EVTs in placental bed by thick arrows. All photographed with 40X 
objective lens.  
Fig. 2. OATP1A2 and OATP4A1 ontogeny in human placenta. A, B: Relative mRNA 
expression (mean +/- sem) in human placentae from 6 to 34 wks compared to term, given 430 
an arbitrary value of 1; *p<0.05 compared to term. C, D: Western blot on placental 
homogenates from normal human placentae (8 to 39 wks) demonstrated multiple bands 
between 60 and 85kDa representing different glycosylated states with the OATP1A2 
antibody [37, 38] and a single band at ~60kDa for OATP4A1 [35]. Immunoblotting for -
actin on the same blot was used to assess protein loading. Relative densitometry of the 435 
protein bands is shown below the corresponding blot. E, F: Representative sections 
demonstrating immunoreactivity of OATP1A2 and OATP4A1 in 1st trimester (E1, F1), term 
(E2, F2) placenta and in 1st trimester placental bed (E3, F3). Villous cytotrophoblasts are 
21 
shown by arrows, syncytiotrophoblasts by arrowheads and EVTs in placental bed by thick 
arrows. All photographed with 40X objective lens.  440 
Fig. 3. LAT1, LAT2 and CD98 ontogeny in human placenta. A-C: Relative mRNA 
expression (mean +/- sem) in normal human placentae from 6 to 34 wks compared to 
term, given an arbitrary value of 1; *p<0.05, **p<0.01, ***p<0.001 compared to term. D: 
CD98 Western blot on placental homogenates from normal human placentae (8 to 39 wks) 
demonstrated a broad band with two distinct species at 75 and 100kDa representing 445 
different glycosylation states of CD98 [25]. Immunoblotting for -actin on the same blot 
was used to assess protein loading. D: Densitometry of the protein bands is shown below 
the corresponding blot. 
Fig. 4. MCT8 and MCT10 expression in IUGR and AGA placentae. A, D: Relative 
mRNA expression of MCT8 or MCT10 in early (25-32 wks) and late (37-38 wks) 3rd 450 
trimester IUGR placentae compared to gestationally-matched AGA controls (27-34 wks 
and 37-41 wks respectively). Scatter dot plots represent individual relative expression with 
mean (dotted line) and sem. B, E: Representative Western blots showing MCT8 and 
MCT10 protein in placental homogenates from early and late 3rd trimester pregnancies 
complicated by IUGR and AGA placentae. Immunoblotting for -actin on the same blots 455 
was used to assess protein loading. C, F: Relative densitometry analysis of MCT8 and 
MCT10 protein expression respectively. MCT8: pooled data from 2 separate Western blots 
including a total of 8 IUGR and 8 AGA samples; MCT10: pooled data from 3 separate 
Western blots including a total of 4 IUGR and 4 AGA samples; *p<0.05. 
Fig. 5. OATP1A2, OATP4A1, LAT1, LAT2 and CD98 expression in IUGR and AGA 460 
placentae. Relative mRNA expression in IUGR human placentae (early: 25-32 wks and 
late: 37-38 wks 3rd trimester gestational groups) compared to gestationally-matched AGA 
controls (27-34 wks and 37-41 wks respectively); Scatter dot plots represent individual 
22 
relative expression with mean (dotted line) and sem. Analysis using 2-way ANOVA 
showed no significant differences. 465 
23 
References: 
[1] Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J et al. Maternal 
thyroid deficiency during pregnancy and subsequent neuropsychological development of 
the child. N Engl J Med 1999; 341:549-55. 470 
[2] Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL and de Vijlder JJ. Maternal 
hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year 
follow-up study. Clin Endocrinol 2003; 59:282-8. 
[3] de Escobar GM, Obregon MJ and del Rey FE. Maternal thyroid hormones early in 
pregnancy and fetal brain development. Best Pract Res Clin Endocrinol Metab 2004; 475 
18:225-48. 
[4] Chan S, Kachilele S, McCabe CJ, Tannahill LA, Boelaert K, Gittoes NJ et al. Early 
expression of thyroid hormone deiodinases and receptors in human fetal cerebral cortex. 
Brain Res Dev Brain Res 2002; 138:109-16. 
[5] Chan S, Franklyn JA and Kilby M. Maternal thyroid hormones and fetal brain 480 
development. Current Opinion in Endocrinology & Diabetes 2005; 12:23-30. 
[6] Calvo RM, Jauniaux E, Gulbis B, Asuncion M, Gervy C, Contempre B et al. Fetal 
tissues are exposed to biologically relevant free thyroxine concentrations during early 
phases of development. J Clin Endocrinol Metab 2002; 87:1768-77. 
[7] Costa A, Arisio R, Benedetto C, Bertino E, Fabris C, Giraudi G et al. Thyroid hormones 485 
in tissues from human embryos and fetuses. J Endocrinol Invest 1991; 14:559-68. 
[8] Vulsma T, Gons MH and de Vijlder JJ. Maternal-fetal transfer of thyroxine in congenital 
hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989; 
321:13-6. 
[9] Kilby MD, Verhaeg J, Gittoes N, Somerset DA, Clark PM and Franklyn JA. Circulating 490 
thyroid hormone concentrations and placental thyroid hormone receptor expression in 
normal human pregnancy and pregnancy complicated by intrauterine growth restriction 
(IUGR). J Clin Endocrinol Metab 1998; 83:2964-71. 
[10] Barber KJ, Franklyn JA, McCabe CJ, Khanim FL, Bulmer JN, Whitley GS et al. The in 
vitro effects of triiodothyronine on epidermal growth factor-induced trophoblast function. J 495 
Clin Endocrinol Metab 2005; 90:1655-61. 
[11] Maruo T, Matsuo H and Mochizuki M. Thyroid hormone as a biological amplifier of 
differentiated trophoblast function in early pregnancy. Acta Endocrinol 1991; 125:58-66. 
[12] Oki N, Matsuo H, Nakago S, Murakoshi H, Laoag-Fernandez JB and Maruo T. Effects 
of 3,5,3'-triiodothyronine on the invasive potential and the expression of integrins and 500 
matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin 
Endocrinol Metab 2004; 89:5213-21. 
[13] LaFranchi SH, Haddow JE and Hollowell JG. Is thyroid inadequacy during gestation a 
risk factor for adverse pregnancy and developmental outcomes? Thyroid 2005; 15:60-71. 
[14] Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A and Levalle O. Overt and 505 
subclinical hypothyroidism complicating pregnancy. Thyroid 2002; 12:63-8. 
[15] Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ et al. Subclinical 
hypothyroidism and pregnancy outcomes. Obstet Gynecol 2005; 105:239-45. 
[16] Visser WE, Friesema EC, Jansen J and Visser TJ. Thyroid hormone transport in and 
out of cells. Trends Endocrinol Metab 2008; 19:50-6. 510 
24 
[17] Dumitrescu AM, Liao XH, Best TB, Brockmann K and Refetoff S. A novel syndrome 
combining thyroid and neurological abnormalities is associated with mutations in a 
monocarboxylate transporter gene. Am J Hum Genet 2004; 74:168-75. 
[18] Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M et al. 
Association between mutations in a thyroid hormone transporter and severe X-linked 515 
psychomotor retardation. Lancet 2004; 364:1435-7. 
[19] Schwartz CE, May MM, Carpenter NJ, Rogers RC, Martin J, Bialer MG et al. Allan-
Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J 
Hum Genet 2005; 77:41-53. 
[20] Heuer H, Maier MK, Iden S, Mittag J, Friesema EC, Visser TJ et al. The 520 
monocarboxylate transporter 8 linked to human psychomotor retardation is highly 
expressed in thyroid hormone-sensitive neuron populations. Endocrinology 2005; 
146:1701-6. 
[21] Chan SY, Franklyn JA, Pemberton HN, Bulmer JN, Visser TJ, McCabe CJ et al. 
Monocarboxylate transporter 8 expression in the human placenta: the effects of severe 525 
intrauterine growth restriction. J Endocrinol 2006; 189:465-71. 
[22] Park SY, Kim J-K, Kim IJ, Choi BK, Jung KY, Lee S et al. Reabsorption of neutral 
amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral 
membrane of proximal tubule. Archives of Pharmacal Research 2005; 28:421-32. 
[23] Patel P, Weerasekera N, Hitchins M, Boyd CA, Johnston DG and Williamson C. Semi 530 
quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C,OATP-D, 
OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta 
2003; 24:39-44. 
[24] Pineda M, Fernandez E, Torrents D, Estevez R, Lopez C, Camps M et al. 
Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an 535 
L-type amino acid transport activity with broad specificity for small and large zwitterionic 
amino acids. Journal of Biological Chemistry 1999; 274:19738-44. 
[25] Ritchie JW and Taylor PM. Role of the System L permease LAT1 in amino acid and 
iodothyronine transport in placenta. Biochem J 2001; 356:719-25. 
[26] Sato K, Sugawara J, Sato T, Mizutamari H, Suzuki T, Ito A et al. Expression of 540 
organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta 2003; 
24:144-8. 
[27] Khong TY. Pathology of intrauterine growth retardation. Am J Reprod Immunol 1989; 
21:132-6. 
[28] Fattal-Valevski A, Leitner Y, Kutai M, Tal-Posener E, Tomer A, Lieberman D et al. 545 
Neurodevelopmental outcome in children with intrauterine growth retardation: a 3-year 
follow-up. J Child Neurol 1999; 14:724-7. 
[29] Larroque B, Bertrais S, Czernichow P and Leger J. School difficulties in 20-year-olds 
who were born small for gestational age at term in a regional cohort study. Pediatrics 
2001; 108:111-5. 550 
[30] Kilby MD, Barber K, Hobbs E and Franklyn JA. Thyroid hormone action in the 
placenta. Placenta 2005; 26:105-13. 
[31] Thorpe-Beeston JG, Nicolaides KH, Snijders RJ, Felton CV and McGregor AM. 
Thyroid function in small for gestational age fetuses. Obstet Gynecol 1991; 77:701-6. 
25 
[32] Chan S, Kachilele S, Hobbs E, Bulmer JN, Boelaert K, McCabe CJ et al. Placental 555 
iodothyronine deiodinase expression in normal and growth-restricted human pregnancies. 
J Clin Endocrinol Metab 2003; 88:4488-95. 
[33] Robson SC, Simpson H, Ball E, Lyall F and Bulmer JN. Punch biopsy of the human 
placental bed. Am J Obstet Gynecol 2002; 187:1349-55. 
[34] Ramadan T, Camargo SM, Summa V, Hunziker P, Chesnov S, Pos KM et al. 560 
Basolateral aromatic amino acid transporter TAT1 (Slc16a10) functions as an efflux 
pathway. J Cell Physiol 2006; 206:771-9. 
[35] Huber RD, Gao B, Sidler Pfandler MA, Zhang-Fu W, Leuthold S, Hagenbuch B et al. 
Characterization of two splice variants of human organic anion transporting polypeptide 
3A1 isolated from human brain. Am J Physiol Cell Physiol 2007; 292:C795-806. 565 
[36] James SR, Franklyn JA, Reaves BJ, Smith VE, Chan SY, Barrett TG et al. 
Monocarboxylate transporter 8 in neuronal cell growth. Endocrinology 2009; 150:1961-9. 
[37] Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A and Meier PJ. Organic 
anion-transporting polypeptides mediate transport of opioid peptides across blood-brain 
barrier. J Pharmacol Exp Ther 2000; 294:73-9. 570 
[38] Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, Hagenbuch B et al. 
Chlorambucil-taurocholate is transported by bile acid carriers expressed in human 
hepatocellular carcinomas. Gastroenterology 1997; 113:1295-305. 
[39] Ayuk PT, Sibley CP, Donnai P, D'Souza S and Glazier JD. Development and 
polarization of cationic amino acid transporters and regulators in the human placenta. Am 575 
J Physiol Cell Physiol 2000; 278:C1162-71. 
[40] Okamoto Y, Sakata M, Ogura K, Yamamoto T, Yamaguchi M, Tasaka K et al. 
Expression and regulation of 4F2hc and hLAT1 in human trophoblasts. American Journal 
of Physiology - Cell Physiology 2002; 282:C196-204. 
[41] Hoeltzli SD and Smith CH. Alanine transport systems in isolated basal plasma 580 
membrane of human placenta. Am J Physiol 1989; 256:C630-7. 
[42] Lewis RM, Glazier J, Greenwood SL, Bennett EJ, Godfrey KM, Jackson AA et al. L-
serine uptake by human placental microvillous membrane vesicles. Placenta 2007; 
28:445-52. 
[43] Laoag-Fernandez JB, Matsuo H, Murakoshi H, Hamada AL, Tsang BK and Maruo T. 585 
3,5,3'-Triiodothyronine down-regulates Fas and Fas ligand expression and suppresses 
caspase-3 and poly (adenosine 5'-diphosphate-ribose) polymerase cleavage and 
apoptosis in early placental extravillous trophoblasts in vitro. J Clin Endocrinol Metab 
2004; 89:4069-77. 
[44] Benirschke K, Kaufmann P and Baergen RN. Architecture of normal villous trees. In: 590 
Verlag, ed. Pathology of the human placenta: Springer, 2006. 
[45] Hume R, Simpson J, Delahunty C, van Toor H, Wu SY, Williams FL et al. Human fetal 
and cord serum thyroid hormones: developmental trends and interrelationships. Journal of 
Clinical Endocrinology & Metabolism 2004; 89:4097-103. 
[46] Fisher DA. Fetal thyroid function: diagnosis and management of fetal thyroid 595 
disorders. Clin Obstet Gynecol 1997; 40:16-31. 
[47] Herrero E, Diez-Guerra J, Aragon MC, Valdivieso F and Gimenez C. Developmental 
studies on the uptake of tyrosine by synaptosomes and plasma membrane vesicles 
derived from rat brain. Effect of thyroid hormones. Int J Dev Neurosci 1986; 4:13-20. 
26 
[48] Capelo LP, Beber EH, Fonseca TL and Gouveia CH. The monocarboxylate 600 
transporter 8 and L-type amino acid transporters 1 and 2 are expressed in mouse 
skeletons and in osteoblastic MC3T3-E1 cells. Thyroid 2009; 19:171-80. 
[49] Zlender V, Breljak D, Ljubojevic M, Flajs D, Balen D, Brzica H et al. Low doses of 
ochratoxin A upregulate the protein expression of organic anion transporters Oat1, Oat2, 
Oat3 and Oat5 in rat kidney cortex. Toxicol Appl Pharmacol 2009; 239:284-96. 605 
[50] Jansson T, Scholtbach V and Powell TL. Placental transport of leucine and lysine is 
reduced in intrauterine growth restriction. Pediatric Research 1998; 44:532-7. 
[51] Roos S, Jansson N, Palmberg I, Saljo K, Powell TL and Jansson T. Mammalian target 
of rapamycin in the human placenta regulates leucine transport and is down-regulated in 
restricted fetal growth. J Physiol 2007; 582:449-59. 610 
[52] Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP and Visser TJ. 
Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J 
Biol Chem 2003; 278:40128-35. 
[53] Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y et al. The human 
T-type amino acid transporter-1: characterization, gene organization, and chromosomal 615 
location. Genomics 2002; 79:95-103. 
[54] Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH and Visser TJ. 
Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate 
transporter 10. Mol Endocrinol 2008; 22:1357-69. 
[55] Friesema EC, Docter R, Moerings EP, Verrey F, Krenning EP, Hennemann G et al. 620 
Thyroid hormone transport by the heterodimeric human system L amino acid transporter. 
Endocrinology 2001; 142:4339-48. 
[56] Hagenbuch B. Cellular entry of thyroid hormones by organic anion transporting 
polypeptides. Best Pract Res Clin Endocrinol Metab 2007; 21:209-21. 
[57] Hagenbuch B and Meier PJ. The superfamily of organic anion transporting 625 
polypeptides. Biochim Biophys Acta 2003; 1609:1-18. 
[58] Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M et al. Identification of 
thyroid hormone transporters in humans: different molecules are involved in a tissue-
specific manner. Endocrinology 2001; 142:2005-12. 
[59] Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F et al. 630 
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with 
three other OATPs of human liver. Gastroenterology 2001; 120:525-33. 
TA
BL
E 
1:
 C
ha
ra
ct
er
is
tic
s 
of
 th
e 
th
yr
oi
d 
ho
rm
on
e 
tra
ns
po
rte
rs
 p
re
se
nt
 in
 th
e 
pl
ac
en
ta
 
 On
ly
 s
om
e 
of
 t
he
 K
m
 v
al
ue
s 
ha
ve
 b
ee
n 
de
te
rm
in
ed
 m
ai
nl
y 
fro
m
 s
tu
di
es
 u
si
ng
 
Xe
no
pu
s 
lae
vis
 o
oc
yt
es
: 
M
C
T8
, 
LA
T-
C
D
98
, 
O
AT
P
1A
2,
 
O
A
TP
4A
1.
*T
he
 in
de
pe
nd
en
t e
xp
re
ss
io
n 
of
 th
e 
hu
m
an
 M
C
T8
 o
r 
M
C
T1
0 
in
 C
O
S
1 
ce
lls
 b
ot
h 
sh
ow
ed
 a
 g
re
at
er
 p
re
fe
re
nc
e 
fo
r 
T3
 th
an
 T
4 
up
ta
ke
. 
W
hi
ls
t 
M
C
T1
0 
sh
ow
ed
 a
 g
re
at
er
 a
bi
lit
y 
to
 t
ra
ns
po
rt 
T3
 c
om
pa
re
d 
to
 M
C
T8
, 
M
C
T8
 w
as
 f
ou
nd
 t
o 
be
 a
 m
or
e 
po
te
nt
 t
ra
ns
po
rte
r 
of
 T
4.
 T
he
 
lo
ca
lis
at
io
ns
 
of
 
th
e 
tra
ns
po
rte
rs
 
in
cl
ud
e 
da
ta
 
fro
m
 
pr
ev
io
us
ly
 
pu
bl
is
he
d 
re
po
rts
 
an
d 
fro
m
 
th
is
 
cu
rre
nt
 
st
ud
y.
 
ST
=s
yn
cy
tio
tro
ph
ob
la
st
; 
C
T=
cy
to
tro
ph
ob
la
st
; E
V
T=
ex
tra
vi
llo
us
 tr
op
ho
bl
as
t. 
  
  
  
  
  
  
  
 
  
 
Pr
ot
ei
n 
Ge
ne
 
Km
 fo
r 
T4
 (μ
M
) 
Km
 fo
r T
3 
(μ
M
) 
Km
 fo
r 
rT
3 
(μ
M
) 
Ot
he
r 
co
m
po
un
ds
 
tra
ns
po
rte
d 
K
m
 (μ
M
) f
or
 o
th
er
 
co
m
po
un
ds
 
Re
fe
re
nc
es
 
Lo
ca
lis
at
io
n 
in
 p
la
ce
nt
a 
Re
fe
re
nc
es
 
  
  
  
  
  
  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
M
CT
8 
SL
C
16
A
2 
4.
7 
(r
at
) 
4.
0 
(r
at
) 
2.
2 
(r
at
) 
U
nk
no
w
n 
N
A
 
 
ST
, C
T,
 E
VT
, d
ec
id
ua
l 
st
ro
m
a 
[2
1,
 5
2]
 
M
CT
10
 
SL
C
16
A
10
 
*H
ig
he
r 
th
an
 fo
r 
T3
 
*L
ow
er
 o
r t
he
 
sa
m
e 
as
 
M
C
T8
 
? 
Ar
om
at
ic
 a
m
in
o 
ac
id
s 
45
0-
75
0 
[5
3]
 
ST
, C
T,
 E
VT
, v
illo
us
 s
tro
m
a,
 
de
ci
du
al
 s
tro
m
a 
[5
4,
 3
4]
 
LA
T1
 
SL
C
7A
5 
7.
9 
0.
8 
12
.5
 
La
rg
e 
ne
ut
ra
l 
am
in
o 
ac
id
s 
30
-9
4 
[2
2]
 
ST
 (a
pi
ca
l) 
[5
5,
 4
1,
 
25
] 
LA
T2
 
SL
C
7A
8 
??
 
OA
TP
1A
2 
SL
C
O
1A
2 
8 
6.
5 
? 
or
ga
ni
c 
an
io
ns
, 
ne
ut
ra
l 
co
m
po
un
ds
, 
ca
tio
ns
 
5-
60
 
[5
6,
 5
7]
 
ST
, C
T,
 E
VT
 
[5
8,
 5
9]
 
OA
TP
4A
1 
SL
C
O
4A
1 
 ?
 
0.
9 
? 
Bi
le
 s
al
ts
, S
te
ro
id
 
co
nj
ug
at
es
, P
G
E
2,
 
be
nz
yl
pe
ni
cl
lin
 
14
 
[5
6,
 5
7]
 
ST
 
[5
8,
 2
6]
 
Ta
bl
e
TA
BL
E 
2:
 R
ea
l-t
im
e 
R
T-
P
C
R
 P
rim
er
s 
an
d 
pr
ob
es
 s
eq
ue
nc
es
 
 
Ge
ne
 
Ac
ce
ss
io
n 
nu
m
be
r 
Fo
rw
ar
d 
pr
im
er
 
Re
ve
rs
e 
pr
im
er
 
Pr
ob
e 
Am
pl
ic
on
 
le
ng
th
 (b
p)
 
M
CT
8 
N
M
00
65
17
 
C
AA
C
G
C
AC
TT
AC
C
G
C
AT
C
TG
 
G
TA
G
C
C
C
C
AA
TA
C
A 
AC
C
AA
G
AG
 
TC
C
A
C
AT
AC
TT
C
AT
C
AG
G
TG
TA
C
AT
AG
G
G
AA
C
AA
A
 
15
0 
M
CT
10
 
N
M
01
85
93
 
G
AT
TC
AT
G
TC
TA
TA
C
C
C
A
TG
AC
TG
TT
G
 
C
AC
AT
C
AT
AG
G
AG
C
C
C
A
G
TT
TG
T 
C
C
C
A
C
C
C
A
TT
G
C
A
G
G
G
TT
AC
TT
C
G
T 
77
 
OA
TP
1A
2 
N
M
13
44
31
 
G
TG
AA
C
AC
AG
AT
G
AT
C
TG
AT
C
AT
AA
C
TC
 
AA
C
TC
C
TG
C
AC
A
AA
TC
A
G
AA
AG
C
 
AT
G
C
AC
C
G
AC
C
C
A
AC
G
A
G
TG
TC
AG
T 
87
 
OA
TP
4A
1 
N
M
01
63
54
 
G
C
AG
C
C
A
C
G
G
AG
AC
G
AA
 
AA
AG
AT
TC
TG
AG
G
G
AT
AC
AG
C
TA
C
AG
T 
C
TC
G
G
TA
C
AC
C
TT
C
TG
G
C
C
G
TC
C
A
 
70
 
LA
T1
 
N
M
00
34
86
 
AA
AT
G
AT
C
AA
C
C
C
C
TA
C
A
G
AA
AC
C
T 
AC
G
TA
C
AC
C
AG
C
G
TC
AC
G
AT
 
C
C
TG
G
C
C
A
TC
AT
C
AT
C
TC
C
C
TG
C
C
 
73
 
LA
T2
 
N
M
01
22
44
 
AA
AT
C
TG
G
AG
G
TG
AC
TA
C
TC
C
TA
TG
TC
 
G
AT
C
AC
C
A
G
C
AC
AG
C
A
A
TC
C
 
AG
C
C
TC
AG
G
AA
C
C
C
AG
C
C
AG
TC
C
T 
87
 
CD
98
 
N
M
00
10
12
66
1 
TG
AG
AT
TG
G
C
C
TG
G
AT
G
C
A
 
G
G
AC
TC
AT
C
C
C
A
C
AG
C
A
TG
AC
 
C
C
C
TT
C
C
TG
G
AC
A
G
C
C
TA
TG
G
AG
G
C
 
73
 
Ta
bl
e
MCT8
(n=2) (n=3) (n=4)
A B
C D
H
H1 H2 H3
β-actin
50
75
50
37
kDa
JEG3E
***
***+
(n=39) (n=18) (n=4) (n=9) (n=40)
Gestational age (weeks)
***++ **
(n=39) (n=18) (n=4) (n=9) (n=40)
Gestational age (weeks)
F G
MCT8 MCT10
kDa 8 10 13 14 20 40 38 39 weeks
50
50
37
β-actin
8 10 13 19 20 31.6 34 37.5 39 weeks
50
kDa
75
50
β-actin
MCT10
(n=2) (n=3) (n=3)
50 M25 M25 M
*
Figure
A B
* *
C D100
75
50
50
8 10 13 14 20 37 38 3934 weekskDa
OATP1A2
β-actin
E
F
E:1 E:2 E:3
F:1 F:3F:2
75
50
kDa
β-actin
393837201413108 weeks
OATP4A1
50
*
(n=39) (n=18) (n=4) (n=9) (n=40)
Gestational age (weeks)
(n=39) (n=18) (n=4) (n=9) (n=40)
Gestational age (weeks)
OATP1A2 OATP4A1
(n=2) (n=3) (n=4) (n=2) (n=3) (n=3)
50M
50M50M
50M 25M
25M
Figure
105
75
50
35
*
(n=39) (n=18) (n=4) (n=9) (n=40)
Gestational age (weeks)
C
D
kDa 3937.431.7312019131008 wks
actin
CD98
(n=39) (n=18) (n=4) (n=9) (n=40)
Gestational age (weeks)
LAT2
*** *** **
(n=39) (n=18) (n=4) (n=9) (n=40)
Gestational age (weeks)
B
LAT1
CD98
A
(n=2) (n=3) (n=4)
Figure
BD
E
*A
AGA - LATEIUGR - LATE
MCT8
β actin50
37
75
50
50
37
75
50
IUGR - EARLY AGA - EARLY
MCT8
β actin
50
100
75
50
37
IUGR
Early
AGA
Early
IUGR
Late
AGA
Late
MCT10
β actin
Early 3rd Trim
(n=17) (n=9)
Late 3rd Trim
(n=5) (n=40)
Early 3rd Trim
(n=17) (n=9)
Late 3rd Trim
(n=5) (n=40)
*C F
MCT10MCT8
kDa
kDa
Early 3rd Trim Late 3rd Trim Early 3rd Trim Late 3rd Trim
(n=4) (n=4)(n=4) (n=4) (n=2) (n=2)(n=2)(n=2)
Figure
AB
C
D
E
Early 3rd Trim
(n=17) (n=9)
Late 3rd Trim
(n=5) (n=40)
Early 3rd Trim
(n=17) (n=9)
Early 3rd Trim
(n=17) (n=9)
Early 3rd Trim
(n=17) (n=9)
Early 3rd Trim
(n=17) (n=9)
Late 3rd Trim
(n=5) (n=40)
Late 3rd Trim
(n=5) (n=40)
Late 3rd Trim
(n=5) (n=40)
Late 3rd Trim
(n=5) (n=40)
Figure
